Skip to main content
. 2021 Nov 4;9(11):e002837. doi: 10.1136/jitc-2021-002837

Figure 7.

Figure 7

NK cell marker mRNA levels are increased in human pancreatic cancer tumors and predictive of survival. (A) CIBERSORT scores representing the relative abundance of various immune cell types derived from RNAseq data from TCGA for pancreatic adenocarcinoma (PAAD) and skin cutaneous melanoma (SKCM). (B) Overall survival curves demonstrating there is no significant difference in survival in TCGA PDAC patients with high (top 50%) vs low (bottom 50%) mRNA expression levels of T cell markers (CD3, CD4 and CD8A). (C) Overall survival curves demonstrating TCGA PDAC patients with high levels (top 50%) of NK cell marker CD56 and NK cell activation marker LAMP1 have significantly longer overall survival compared with PDAC patients with low expression (bottom 50%) of CD56 or LAMP1. PDAC, pancreatic ductal adenocarcinoma; TCGA, The Cancer Genome Atlas.